Nanomedicine for Ischemic Cardiomyopathy: Progress, Opportunities, and Challenges

Cover
NANOMEDICINE
FOR ISCHEMIC
CARDIOMYOPATHY
Progress, Opportunities,
and Challenges
Copyright
Contributors
1
Ischemic cardiomyopathy
	Pathophysiology of heart failure
	Pathophysiology of stunned or hibernating myocardium
	Reperfusion injury
	Clinical implications
		Stages in the development of heart failure
	References
2
Nanotechnology and nanomedicine
	Brief history of nanotechnology
	Brief history of nanomedicine
	Synopsis of recent advances in nanomedicine
	Future of nanomedicine
	Overview of nanotechnology in cardiology
	References
3
Atherosclerosis and thrombosis heart failure
	Prevention of heart failure in atherosclerotic conditions
	Nanoparticulate systems for the prognosis and treatment of coronary atherosclerosis
	Nanotechnologies for diagnosis and treatment of thrombosis
	Conclusion
	References
4
Device-based treatment of heart failure
	Implantable cardioverter-defibrillators
	Cardiac resynchronization therapy
	Treatment for refractory heart failure
		Mechanical circulatory support systems
		Cardiac transplantation
		Surgical ventricular reconstruction
		Cardiac contractility modulation
	References
5
Stem cells and heart tissue regeneration
	Introduction
	Fibrosis after MI
	Conventional therapies in HF
	Cardiac regeneration
	Cardiac cell therapy and tissue engineering
	Struggles in cardiac cell therapy
	Cell maturity and heart regeneration
	Stem cells in heart regeneration
		Bone marrow stem cells
		Cardiac and cardiosphere-derived stem cells
		Induced pluripotent stem cells
		Embryonic stem cells
		Umbilical cord stem cells
		Adipose-derived stem cells
	Conclusion
	References
6
Exosomes as natural nanocarriers for therapeutic and diagnostic use in cardiovascular diseases
	Introduction
	Biogenesis and composition of the exosomes
	The therapeutic potential of endogenous exosomes in an ischemia-injury heart
		Cardiomyocyte-derived exosomes
		Cardiac endothelial cell-derived exosomes
		Cardiac fibroblast-derived exosomes
		Cardiac progenitor cell-derived exosomes
	Stem cell-derived exosomes
		Mesenchymal stem cell-derived exosomes
		Exosomes from induced pluripotent stem cells (iPSCs) and iPSCs derivatives
		Exosomes with artificially modified cargo
	Biodistribution of exosomes in vivo
	Exosomes as biomarkers of cardiovascular disease
	Conclusion and future perspective
	References
7
Use of nanoparticulate systems to salvage the myocardium
	Overview of micro- and nanoparticulate-based medicines for cardiovascular diseases
	Nanoparticles
	Nanoparticles for MI
		Nontargeted
		Targeted
		Size
		Shape
		Surface charge
		Surface composition
		Elasticity and degradation
	Administration routes
	Targeting approaches
		Passive targeting
		Active targeting
	References
8
Nanoparticulate systems for monitoring of therapeutic cells
	Stem cell therapy for cardiac repair
	Potential mechanisms of adult SCs in cardiovascular regeneration
	Different kinds of stem cells for heart treatment:
	Stem cell and NP integration
	NPs for genetic engineering in stem cells
	Stem cell targeting
	MRI tracking
	Optical tracking
	Multimodal tracking
	Stem cell retention
	Stem cell therapy potential
	References
9
Cell-nanoparticle interactions
	In vitro studies
	References
10
Nanoparticulate systems for delivery of biomolecules and cells to the injured myocardium
	Polymer-based nanodelivery systems
	Lipid-based nanodelivery systems
	Nucleic acid-based nanodelivery systems
	Cell-based nanodelivery systems
	Imaging nanodelivery systems
	Nanoparticles as sensors for detection of cardiac biomarkers
	References
	Further reading
11
Nanoparticulate systems for sustained delivery of paracrine factors
	Different types of nanoparticulate systems for encapsulation and delivery of paracrine factors
	Lipid-based delivery systems
	Polymer-based delivery systems
		Synthetic polymers
		Natural polymers
	Inorganic nanoparticulate systems for growth factor delivery
	Nanofibers for growth factor delivery
	Nanoparticle-embedded scaffolds as a growth factor delivery strategy
	References
	Further reading
12
Nano-bioink solutions for cardiac tissue bioprinting
	Nanomaterials in cardiac bioinks
	Electrical conductivity of bioinks
	Imaging properties of bioinks
	Mechanical and biochemical properties of nano-bioinks
	DNA-NP bioinks
	Antibacterial nano-bioinks
	Conclusions and future perspectives
	References
13
Clinical cardiovascular medicine and lessons learned from cancer nanotechnology
	Tissue/bioengineering approaches in clinical cardiovascular medicine
	Lessons learned in cancer nanotechnology facilitates successful clinical translation of cardiac nanotechnology
	Conclusions
	References
Index
	A
	B
	C
	D
	E
	F
	G
	H
	I
	K
	L
	M
	N
	O
	P
	Q
	R
	S
	T
	U
	V
	W
	X
Back Cover